biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Here's the bottom line.

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 13, 2022 8:44pm

134 Views

Post# 35169898

RE:Here's the bottom line.

What's the market cap of the new company?
How much cash?
Does it have the financial wherewithal, scientific teams, and clinical trial infrastructure to advance xB3 on its own with the other clinical stage assets and to enter more substantial strategic alliances, etc.
How can the various technology be used together?
How undervalued was the other company itself helping to offset some of the undervaluation to BTI?

BTI has been unable to advance for years. Is this new company now viable with cash, clinical trial infrastructure, newsflow from multiple clinical assets, and a NASDAQ listing, etc.?

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages